小容量注射劑市場－全球產業規模、佔有率、趨勢、機會及預測（依劑型、類型、包裝、適應症、地區及競爭格局分類，2021-2031年）

全球小容量注射劑市場預計將從 2025 年的 2,065.5 億美元成長到 2031 年的 3,108.5 億美元，年複合成長率為 7.05%。

小容量注射劑是指包裝在100毫升或以下容器的無菌注射液，是麻醉劑、診斷試劑和藥品給藥的必需品。此市場成長的主要促進因素是需要即時治療的慢性疾病發病率不斷上升，以及重症監護環境中對便捷注​​射劑型的需求日益成長，從而確保了全球醫療保健系統將繼續依賴這些藥物製劑來支持患者的快速穩定和治療。

然而，該行業面臨著與生產複雜性和維持嚴格的無菌條件相關的重大障礙，這些因素將嚴重損害供應鏈的可靠性。近期有關生產一致性的產業數據凸顯了這項營運挑戰。據美國衛生系統藥劑師協會 (ASHP) 稱，2024 年已確定的新藥短缺中，約 48% 將是注射劑短缺。這項統計數據表明，製造商在滿足全球對這些關鍵無菌產品的高需求的同時，還要遵守嚴格的品質標準，這仍然是一個難題。

市場促進因素

慢性病和文明病的日益增加是全球小容量注射劑市場的主要驅動力，也因此對治療管理所需的穩定無菌注射劑供應產生了根本性的需求。腫瘤和糖尿病等疾病需要經常透過管瓶、安瓿或預填充式注射器注射強效藥物，以有效控制病情進展。這種需求在腫瘤領域尤其突出，因為精準的化療劑量依賴小容量製劑以確保安全性和有效性。值得注意的是，根據美國癌症協會於2024年1月發布的《2024年癌症事實與數據》，預計美國新增癌症病例數將首次超過200萬例，這將進一步增加臨床對注射劑的需求。

同時，生物製藥和生物相似藥產業的快速擴張正在重塑市場格局。這些複雜的製劑通常需要腸外給藥以維持生物利用度。標靶生物製藥療法的興起推動了製劑穩定性的創新，並促使人們傾向於採用能夠簡化給藥的密封系統。這一趨勢也體現在監管結果中。美國食品藥物管理局（FDA）藥物評估與研究中心在其2024年1月發布的《2023年新藥核准情況報告》中指出，共有55種新療法核准，這標誌著注射劑領域的創新再次興起。為了滿足對無菌生產日益成長的需求，各公司正積極擴大其業務規模。例如，諾和諾德公司於2024年6月宣布投資41億美元，用於擴建位於北卡羅來納州的表面處理工程生產基地。

市場挑戰

嚴格的無菌操作和無菌注射劑生產固有的複雜性，對全球小容量注射劑市場構成了重大瓶頸。與口服藥物不同，小容量注射劑通常需要無菌處理，這是一個高度複雜的過程，要求從配製到包裝的整個過程中都必須保持產品無菌，且無需最終滅菌。由於這種複雜性，即使是設施環境條件、設備校準或水質方面的微小偏差，都可能導致即時且長時間的停產，以便調查潛在的污染，從而擾亂生產計劃，並使供應商無法持續滿足全球需求。

生產線的這種不穩定性得到了近期行業統計數據的支持，這些數據凸顯了此類產品類型的脆弱性。 2024年，美國藥典（USP）發布的一份供應鏈風險分析報告顯示，新發現的藥品短缺中，53%是非專利無菌注射。這一數字表明，維持無菌狀態所固有的操作挑戰與產品供應直接相關。當製造商因品質保證方面的高門檻而無法持續生產這些必需產品時，市場將面臨實際的限制，無法滿足現有需求，而這與患者的需求無關。

市場趨勢

即用型 (RTU) 和即用型 (RTA) 藥品的普及正在從根本上改變供應鏈，將滅菌的負擔從製藥公司轉移到包裝供應商。透過使用預先清潔和預滅菌的管瓶、藥筒和注射器，製藥公司可以省去複雜的內部無菌處理步驟，從而加快產品上市速度，並減少在清潔和熱力消毒設備上的資本支出。這種營運模式的轉變對於高價值生技藥品成長了 17%，達到 1.004 億歐元。

同時，在嚴格的環境法規和企業脫碳努力的推動下，市場正策略性地轉向永續和環保的包裝材料。為了減少一次性注射對環境的影響，製造商優先考慮採用低碳生產方法和循環經濟原則來生產玻璃和聚合物容器。這項努力也延伸至節能的生產流程，這些工藝在不影響無菌保證的前提下，顯著減少了範圍 1 和範圍 2 的排放。例如，蕭特製藥在其於 2024 年 1 月發布的《2022/2023 永續發展報告》中指出，其範圍 1 和範圍 2 的二氧化碳排放減少了 60%，並實現了 100% 使用綠色電力，這表明該行業在實現全球氣候中和目標方面取得了進展。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球小劑量注射劑市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 依形態（液體、乾燥劑）
  • 依類型（單劑量、多劑量）
  • 依包裝形式（安瓿瓶、管瓶、預填充式注射器、藥筒、瓶子等）
  • 依適應症（疼痛管理、癌症治療、營養不良、胃腸道疾病/腹瀉、糖尿病、其他）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

6. 北美小容量注射劑市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

7. 歐洲小容量注射劑市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

8. 亞太地區小劑量注射劑市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

9. 中東和非洲小容量注射劑市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

10. 南美洲小容量注射劑市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進要素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 最新進展

第13章 全球小容量注射劑市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的可能性
• 供應商電力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• BML Parenteral Drugs
• Rusoma Laboratories Pvt Ltd
• B Braun Melsungen AG
• Fresenius Kabi AG
• Baxter International Inc.
• Sichuan Kelun Pharmaceutical Co Ltd

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Small Volume Parenteral Market is projected to expand from USD 206.55 Billion in 2025 to USD 310.85 Billion by 2031, reflecting a compound annual growth rate of 7.05%. Small volume parenterals are characterized as sterile injectable products packaged in containers of 100 milliliters or less, which are essential for administering anesthetics, diagnostic agents, and medications. The growth of this market is primarily driven by the increasing incidence of chronic conditions demanding immediate therapeutic action and the rising requirement for convenient injectable dosage forms within critical care environments, ensuring a continued reliance on these pharmaceutical preparations to support rapid patient stabilization and treatment across global healthcare systems.

However, the industry faces substantial obstacles related to manufacturing intricacies and the strict maintenance of sterility, factors that can severely compromise the reliability of the supply chain. This operational challenge is highlighted by recent industry data regarding production consistency; according to the American Society of Health-System Pharmacists, approximately 48% of new drug shortages identified in 2024 were injectable medications. This statistic emphasizes the ongoing difficulty manufacturers encounter in aligning production output with the high global demand for these critical sterile products while simultaneously adhering to rigorous quality standards.

Market Driver

The escalating prevalence of chronic and lifestyle-associated diseases acts as a major catalyst for the Global Small Volume Parenteral Market, creating a fundamental need for a steady supply of sterile injectables for therapeutic management. Conditions such as oncology and diabetes mandate the frequent administration of potent pharmaceutical agents via vials, ampoules, or pre-filled syringes to effectively control disease progression. This demand is especially acute in oncology, where precise chemotherapy dosing relies on small volume formats for safety and efficacy; notably, the American Cancer Society's 'Cancer Facts & Figures 2024' reported in January 2024 that new cancer cases in the United States were projected to exceed 2 million for the first time, signaling an intensifying need for parenteral solutions in clinical settings.

Simultaneously, the market is being reshaped by the rapid expansion of the biologics and biosimilars sector, as these complex formulations generally require parenteral delivery to preserve bioavailability. The transition toward targeted biologic therapies has spurred innovations in formulation stability, favoring containment systems that simplify administration. This trend is reflected in regulatory achievements; the FDA Center for Drug Evaluation and Research noted in its 'New Drug Therapy Approvals 2023' report, released in January 2024, that 55 novel therapeutics were approved, indicating a resurgence in innovation focused on injectables. To accommodate this surging requirement for sterile manufacturing, companies are aggressively scaling operations, such as Novo Nordisk's June 2024 announcement of a $4.1 billion investment to expand its fill and finish footprint in North Carolina.

Market Challenge

The rigorous maintenance of sterility assurance and the inherent complexity of manufacturing sterile injectables create a significant bottleneck for the Global Small Volume Parenteral Market. Unlike oral medications, small volume parenterals frequently require aseptic processing, a highly intricate method where the product must remain sterile throughout formulation and packaging without terminal sterilization. Because of this complexity, even minor deviations in facility environmental conditions, equipment calibration, or water quality can trigger immediate and lengthy production halts to investigate potential contamination, thereby disrupting schedules and preventing suppliers from consistently meeting global volume requirements.

This instability within the production pipeline is substantiated by recent industry statistics highlighting the vulnerability of this specific product category. In 2024, the U.S. Pharmacopeia released an analysis of supply chain risks revealing that 53% of all new drug shortages identified were generic sterile injectable medicines. This figure demonstrates that the specific operational difficulties associated with maintaining sterility directly correlate with product unavailability; when manufacturers are unable to reliably produce these essential units due to the high barrier of quality assurance, the market becomes physically constrained by an inability to fulfill existing demand, regardless of patient need.

Market Trends

The proliferation of Ready-to-Use (RTU) and Ready-to-Administer (RTA) formulations is fundamentally altering the supply chain by shifting the burden of sterilization from pharmaceutical companies to packaging suppliers. By utilizing pre-washed, pre-sterilized vials, cartridges, and syringes, drug manufacturers can bypass complex in-house aseptic processing steps, thereby accelerating time-to-market and reducing capital expenditure on washing and depyrogenation equipment. This operational shift is particularly critical for high-value biologics where containment integrity and speed are paramount, a trend evidenced by the financial performance of key packaging suppliers; according to the Stevanato Group's November 2024 report on third-quarter financial results, revenue from high-value solutions, including pre-sterilized platforms, rose by 17% to €100.4 million.

Concurrently, the market is undergoing a strategic transition toward sustainable and eco-friendly packaging materials, driven by stringent environmental regulations and corporate decarbonization mandates. Manufacturers are increasingly prioritizing low-carbon production methods and circular economy principles for glass and polymer containers to mitigate the environmental footprint of single-use parenterals. This commitment extends to energy-efficient manufacturing processes that drastically lower Scope 1 and Scope 2 emissions without compromising sterility assurance; for instance, Schott Pharma reported in its 'Sustainability Report 2022/2023' in January 2024 that the company achieved a 60% reduction in Scope 1 and Scope 2 CO2 emissions and transitioned to 100% green electricity, underscoring the sector's alignment with global climate neutrality goals.

Key Market Players

• BML Parenteral Drugs
• Rusoma Laboratories Pvt Ltd
• B Braun Melsungen AG
• Fresenius Kabi AG
• Baxter International Inc.
• Sichuan Kelun Pharmaceutical Co Ltd

Report Scope

In this report, the Global Small Volume Parenteral Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Small Volume Parenteral Market, By Form

• Liquid
• Dry

Small Volume Parenteral Market, By Type

• Single-dose
• Multiple-dose

Small Volume Parenteral Market, By Packaging

• Ampoules
• Vials
• Pre-filled Syringes
• Cartridges
• Bottles
• Others

Small Volume Parenteral Market, By Indication

• Pain Management
• Cancer Care
• Malnourishment
• Gastrointestinal Disorder/Diarrhea
• Diabetes
• Others

Small Volume Parenteral Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Small Volume Parenteral Market.

Available Customizations:

Global Small Volume Parenteral Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Small Volume Parenteral Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Form (Liquid, Dry)
  • 5.2.2. By Type (Single-dose, Multiple-dose)
  • 5.2.3. By Packaging (Ampoules, Vials, Pre-filled Syringes, Cartridges, Bottles, Others)
  • 5.2.4. By Indication (Pain Management, Cancer Care, Malnourishment, Gastrointestinal Disorder/Diarrhea, Diabetes, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Small Volume Parenteral Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Form
  • 6.2.2. By Type
  • 6.2.3. By Packaging
  • 6.2.4. By Indication
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Small Volume Parenteral Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Form
      • 6.3.1.2.2. By Type
      • 6.3.1.2.3. By Packaging
      • 6.3.1.2.4. By Indication
  • 6.3.2. Canada Small Volume Parenteral Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Form
      • 6.3.2.2.2. By Type
      • 6.3.2.2.3. By Packaging
      • 6.3.2.2.4. By Indication
  • 6.3.3. Mexico Small Volume Parenteral Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Form
      • 6.3.3.2.2. By Type
      • 6.3.3.2.3. By Packaging
      • 6.3.3.2.4. By Indication

7. Europe Small Volume Parenteral Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Form
  • 7.2.2. By Type
  • 7.2.3. By Packaging
  • 7.2.4. By Indication
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Small Volume Parenteral Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Form
      • 7.3.1.2.2. By Type
      • 7.3.1.2.3. By Packaging
      • 7.3.1.2.4. By Indication
  • 7.3.2. France Small Volume Parenteral Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Form
      • 7.3.2.2.2. By Type
      • 7.3.2.2.3. By Packaging
      • 7.3.2.2.4. By Indication
  • 7.3.3. United Kingdom Small Volume Parenteral Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Form
      • 7.3.3.2.2. By Type
      • 7.3.3.2.3. By Packaging
      • 7.3.3.2.4. By Indication
  • 7.3.4. Italy Small Volume Parenteral Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Form
      • 7.3.4.2.2. By Type
      • 7.3.4.2.3. By Packaging
      • 7.3.4.2.4. By Indication
  • 7.3.5. Spain Small Volume Parenteral Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Form
      • 7.3.5.2.2. By Type
      • 7.3.5.2.3. By Packaging
      • 7.3.5.2.4. By Indication

8. Asia Pacific Small Volume Parenteral Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Form
  • 8.2.2. By Type
  • 8.2.3. By Packaging
  • 8.2.4. By Indication
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Small Volume Parenteral Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Form
      • 8.3.1.2.2. By Type
      • 8.3.1.2.3. By Packaging
      • 8.3.1.2.4. By Indication
  • 8.3.2. India Small Volume Parenteral Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Form
      • 8.3.2.2.2. By Type
      • 8.3.2.2.3. By Packaging
      • 8.3.2.2.4. By Indication
  • 8.3.3. Japan Small Volume Parenteral Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Form
      • 8.3.3.2.2. By Type
      • 8.3.3.2.3. By Packaging
      • 8.3.3.2.4. By Indication
  • 8.3.4. South Korea Small Volume Parenteral Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Form
      • 8.3.4.2.2. By Type
      • 8.3.4.2.3. By Packaging
      • 8.3.4.2.4. By Indication
  • 8.3.5. Australia Small Volume Parenteral Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Form
      • 8.3.5.2.2. By Type
      • 8.3.5.2.3. By Packaging
      • 8.3.5.2.4. By Indication

9. Middle East & Africa Small Volume Parenteral Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Form
  • 9.2.2. By Type
  • 9.2.3. By Packaging
  • 9.2.4. By Indication
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Small Volume Parenteral Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Form
      • 9.3.1.2.2. By Type
      • 9.3.1.2.3. By Packaging
      • 9.3.1.2.4. By Indication
  • 9.3.2. UAE Small Volume Parenteral Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Form
      • 9.3.2.2.2. By Type
      • 9.3.2.2.3. By Packaging
      • 9.3.2.2.4. By Indication
  • 9.3.3. South Africa Small Volume Parenteral Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Form
      • 9.3.3.2.2. By Type
      • 9.3.3.2.3. By Packaging
      • 9.3.3.2.4. By Indication

10. South America Small Volume Parenteral Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Form
  • 10.2.2. By Type
  • 10.2.3. By Packaging
  • 10.2.4. By Indication
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Small Volume Parenteral Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Form
      • 10.3.1.2.2. By Type
      • 10.3.1.2.3. By Packaging
      • 10.3.1.2.4. By Indication
  • 10.3.2. Colombia Small Volume Parenteral Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Form
      • 10.3.2.2.2. By Type
      • 10.3.2.2.3. By Packaging
      • 10.3.2.2.4. By Indication
  • 10.3.3. Argentina Small Volume Parenteral Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Form
      • 10.3.3.2.2. By Type
      • 10.3.3.2.3. By Packaging
      • 10.3.3.2.4. By Indication

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Small Volume Parenteral Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. BML Parenteral Drugs
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Rusoma Laboratories Pvt Ltd
• 15.3. B Braun Melsungen AG
• 15.4. Fresenius Kabi AG
• 15.5. Baxter International Inc.
• 15.6. Sichuan Kelun Pharmaceutical Co Ltd

16. Strategic Recommendations

17. About Us & Disclaimer